Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

The following is a summary of “Identification of molecular clusters and a risk prognosis model for diffuse large B-cell ...

Roche (RHHBY) announced that the European Commission, EC, has approved Columvi in combination with gemcitabine and oxaliplatin for the ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

The following is a summary of “Prognostic role of interim PET-CT demonstrating partial metabolic response in diffuse large ...